Open access
Open access
Powered by Google Translator Translator

Hypertension

Phase 2RCT | Baxdrostat reduces BP in patients with treatment-resistant hypertension.

11 Nov, 2022 | 13:57h | UTC

Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study – TCTMD

New Drug Helps Tame Uncontrolled High Blood Pressure – HealthDay

 


RCT | Chlortalidone and Hydrochlorothiazide resulted in similar reductions of CVD in older patients with hypertension.

7 Nov, 2022 | 12:50h | UTC

News Release (not published yet): No difference in heart outcomes found in use of two diuretics to treat blood pressure – American Heart Association

Commentaries:

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE – TCTMD

Diuretic Comparison Project – DCP – American College of Cardiology

 


RCT | Discontinuing RAS inhibitors in patients with advanced CKD did not result in a slower decline in eGFR.

4 Nov, 2022 | 13:55h | UTC

Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


M-A | Blood pressure lowering and prevention of dementia.

4 Nov, 2022 | 13:46h | UTC

Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis – European Heart Journal

News Release: Best evidence yet that lowering blood pressure can prevent dementia – George Institute for Global Health

Commentary: Meta-Analysis Shows Decrease in Dementia Risk With HTN Treatment – HealthDay 

 


Cross-Sectional Study | Prevalence of and factors associated with high blood pressure among adolescents in India.

3 Nov, 2022 | 13:57h | UTC

Prevalence of and Factors Associated With High Blood Pressure Among Adolescents in India – JAMA Network Open

Invited Commentary: Prevalence of High Blood Pressure Among Youth in India and Association With Future Cardiovascular Disease – JAMA Network Open

 

Commentary on Twitter

 


Cohort Study | ARBs linked to decreased incidence of epilepsy compared with other antihypertensives.

19 Oct, 2022 | 14:18h | UTC

Association Between Angiotensin Receptor Blocker Therapy and Incidence of Epilepsy in Patients With Hypertension – JAMA Neurology (free for a limited period)

Related:

Loneliness and health – Nature Reviews Disease Primers (if the link is paywalled, try this one)

AHA Scientific Statement | Effects of objective and perceived social isolation on cardiovascular and brain health.

The prevalence of loneliness across 113 countries: systematic review and meta-analysis – The BMJ

Social Isolation and Loneliness – World Health Organization

Psychological Distress and Loneliness Reported by US Adults in 2018 and April 2020 – JAMA

Social isolation and loneliness as risk factors for myocardial infarction, stroke and mortality: UK Biobank cohort study of 479 054 men and women – Heart

 


Perspective | The polypill: from concept and evidence to implementation.

18 Oct, 2022 | 12:55h | UTC

The polypill: from concept and evidence to implementation – The Lancet (free registration required)

News Release: The polypill could avoid millions of premature deaths, heart attacks and strokes every year, say leading cardiology experts – McMaster University

Related:

#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.

#ESCCongress – M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention.

Opinion: A new important study supports wider use of the polypill

#AHA20 – Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk

Perspective: Are Polypills and Population-based Treatment the Next Big Things?

The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era

Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population

Randomized Trial: Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases

Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology – Global Heart

Perspective: The Polypill and the Long Journey to Major Impact

Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care

 


Post-trial follow-up | Longer-term all-cause and cardiovascular mortality with intensive blood pressure control.

17 Oct, 2022 | 12:41h | UTC

Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis of a Randomized Clinical Trial – JAMA Cardiology (free for a limited period)

Author Interview: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control – JAMA

Commentaries:

Benefits of Intensive Blood Pressure Control May Not Persist After Trial Intervention – HCP Live

Study Highlights Importance of Long-term Management of Hypertension – Wake Forest University School of Medicine

Related:

SPRINT Trial final report: targeting a systolic BP of less than 120 mm Hg in patients at increased CV risk is associated with improved CV and mortality outcomes but increases the risk of serious adverse events.

Study: Real-world blood pressure measurements vs. measurements taken in the SPRINT trial

Studies: Intensive versus Standard Blood-Pressure Control

 

Commentary on Twitter

 


Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study.

17 Oct, 2022 | 12:37h | UTC

Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study – Nature Medicine

See also:

News Release: New star rating system published in Nature Medicine helps people make informed decisions about diet and healthy habits – Institute for Health Metrics and Evaluation

Commentary: Expert reaction to studies presenting a standardized approach for quantifying the strength of evidence that supports associations between risk factors and health outcomes – Science Media Centre

Homepage: The Burden of Proof Studies – Nature Medicine

The Burden of Proof studies: assessing the evidence of risk

Health effects associated with vegetable consumption: a Burden of Proof study

Health effects associated with consumption of unprocessed red meat: a Burden of Proof study

Health effects associated with smoking: a Burden of Proof study

 

Commentary on Twitter

 


Cohort Study | Visit-to-visit SBP variability linked to increased risk of atrial fibrillation in middle-aged and older populations.

17 Oct, 2022 | 12:30h | UTC

Visit-to-visit SBP variability and risk of atrial fibrillation in middle-aged and older populations – Journal of Hypertension

 


Position Statement | Home blood pressure monitoring.

14 Oct, 2022 | 14:16h | UTC

Home blood pressure monitoring: a position statement from the Korean Society of Hypertension Home Blood Pressure Forum – Clinical Hypertension

Related:

2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement – Journal of Hypertension

Current applications and limitations of European guidelines on blood pressure measurement: implications for clinical practice – Internal and Emergency Medicine

Randomized Diagnostic Study: home blood pressure measurements correlate better with 24-h ambulatory monitoring measurements compared to clinic, and kiosk measurements.

Study suggests a 30-second interval between automated office blood pressure measurements is as accurate and reliable as a 60-second interval.

USPSTF Statement recommends screening for hypertension in adults 18 years or older with office blood pressure measurement – diagnostic confirmation with blood pressure measurements outside of the clinical setting is advised before starting treatment

Study suggests that 7 days of home blood pressure monitoring is likely better than 24h ambulatory monitoring or 3 office measurements

 


RCT | No difference in cardiovascular outcomes with evening vs. morning dosing of usual antihypertensives.

12 Oct, 2022 | 14:01h | UTC

Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial – The Lancet

Related: [News release – not published yet] #ESCCongres – RCT | Evening dosing of blood pressure medication not better than morning dosing.

Related Consensus Statement: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension

Related study (conflicting results): Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction in Randomized Trial

 


Perspective | Hydrochlorothiazide vs. chlorthalidone – what is the difference?

11 Oct, 2022 | 13:40h | UTC

Hydrochlorothiazide Versus Chlorthalidone–What is the Difference? – Circulation (free for a limited period)

Related:

Meta-analysis: Chlorthalidone vs. hydrochlorothiazide

Large Observational Study Suggests Hydrochlorothiazide may be as Effective as Chlortalidone with Less Adverse Effects

 

Commentary on Twitter

 


RCT | Intrapartum extended-release nifedipine to prevent severe intrapartum hypertension in patients with severe preeclampsia.

4 Oct, 2022 | 14:37h | UTC

Trial of Intrapartum Extended-Release Nifedipine to Prevent Severe Hypertension Among Pregnant Individuals With Preeclampsia With Severe Features – Hypertension (link to abstract – $ for full-text)

News Release: Severe preeclampsia treated safely with nifedipine during labor and delivery – American Heart Association

 


ESC Scientific Statement | Sex differences in arterial hypertension.

26 Sep, 2022 | 12:10h | UTC

Sex differences in arterial hypertension: A scientific statement from the ESC Council on Hypertension, the European Association of Preventive Cardiology, Association of Cardiovascular Nursing and Allied Professions, the ESC Council for Cardiology Practice, and the ESC Working Group on Cardiovascular Pharmacotherapy – European Heart Journal

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by-nc/4.0/ license

 


Long-term follow-up of a RCT | Outcomes after catheter-based renal artery denervation for resistant hypertension.

20 Sep, 2022 | 13:33h | UTC

Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial – The Lancet (free registration required)

Commentary: SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss – TCTMD

Original Study: A Controlled Trial of Renal Denervation for Resistant Hypertension – New England Journal of Medicine

 


Nonadherence was revealed through measurements of serum concentrations of antihypertensive drugs in one-third of patients with resistant hypertension previously evaluated as adherent.

11 Sep, 2022 | 22:35h | UTC

Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7‐Year Follow‐Up of Patients Considered Adherent by Directly Observed Therapy – Journal of the American Heart Association

 


Review | The management of hypertensive emergencies—is there a “magical” prescription for all?

8 Sep, 2022 | 14:32h | UTC

The Management of Hypertensive Emergencies—Is There a “Magical” Prescription for All? – Journal of Clinical Medicine

 


Review/Perspective | European hypertension guideline downgrading of beta-blockers is not justified.

31 Aug, 2022 | 11:51h | UTC

Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified – Blood Pressure

 


Salt substitutes vs. regular salt: a quick look.

30 Aug, 2022 | 12:02h | UTC

Salt substitutes vs. regular salt: a quick look – Evidently Cochrane

Original Study: Replacing salt with low‐sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women – Cochrane Library

Related:

Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis – Heart (link to abstract – $ for full-text)

Cluster RCT: A household salt substitution intervention is a cost-effective intervention for preventing stroke and improving quality of life.

#ESCCongress – Cluster RCT: Among patients at increased risk for stroke, salt substitution (75% sodium chloride and 25% potassium chloride by mass) reduced the rates of stroke, major cardiovascular events, and death from any cause.

RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients

Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths

Cluster Randomized Trial: Effect of Salt Substitution on Community-wide Blood Pressure and Hypertension Incidence

 

Commentary on Twitter

 


M-A | Urban-rural differences in hypertension prevalence in low-income and middle-income countries, 1990–2020.

30 Aug, 2022 | 11:55h | UTC

Urban-rural differences in hypertension prevalence in low-income and middle-income countries, 1990–2020: A systematic review and meta-analysis – PLOS Medicine

News Release: Study shows urban-rural differences in hypertension prevalence in low-income and middle-income countries – News Medical

 

Commentary on Twitter

 


Study shows an increasing incidence of hypertensive disorders in pregnancy.

30 Aug, 2022 | 11:52h | UTC

Association of Birth Year of Pregnant Individuals With Trends in Hypertensive Disorders of Pregnancy in the United States, 1995-2019 – JAMA Network Open

Commentaries:

Increased incidence of hypertensive disorders of pregnancy in young Americans – News Medical

Hypertensive Disorders in Pregnancy on the Rise – AJMC

 

Commentary on Twitter

 


[News release – not published yet] #ESCCongres – RCT | Evening dosing of blood pressure medication not better than morning dosing.

29 Aug, 2022 | 12:30h | UTC

Evening dosing of blood pressure medication not better than morning dosing – European Society of Cardiology

Related Consensus Statement: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension

Related study (conflicting results): Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction in Randomized Trial

 


Bedtime dosing of antihypertensive medications: systematic review and consensus statement. – “use of bedtime drug dosing of antihypertensive drugs should not be routinely recommended”.

29 Aug, 2022 | 12:28h | UTC

Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension

Related: Evening dosing of blood pressure medication not better than morning dosing – European Society of Cardiology

 


RCT | Self-measurement of blood pressure with a standard device is not enhanced by the use of a connected smartphone application.

26 Aug, 2022 | 13:29h | UTC

Effectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application: A Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)

News Release: For Checking Blood Pressure at Home, Basic Cuffs Are Just as Good – UC San Francisco

Commentary: App-enabled device no better than standard device for self-measuring blood pressure – ACP Internist

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.